Tag: CBT > CBD FDA: Page 6

Legislation and Regulation

Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Curaleaf Holdings, Inc.

Bragar Eagel & Squire encourages curaleaf investors to contact the firm.

August 6, 2019

Legislation and Regulation

Curaleaf Retracts CBD Health Claims After FDA Warning, New York Decriminalizes Cannabis: Week in Review

Curaleaf has scrubbed its website and social media accounts of health claims about its CBD products in response to a warning from the Food and Drug Administration.

August 3, 2019

Legislation and Regulation

Rep. Antonio Delgado Authors Letter with House Small Business Committee Members Supporting Economic Opportunities From CBD in Farming and Small Business

The letter urges the FDA to provide regulatory guidance on CBD products to support American farmers and entrepreneurs in this growing market.

August 2, 2019

Compliance

Curaleaf Scrubs CBD Health Claims From Its Pages in Response to FDA Warning

Curaleaf “immediately began an extensive review of its website and social media platforms to remove all statements that FDA identified as non-compliant.”

July 29, 2019

Legislation and Regulation

FDA Issues Warning to Curaleaf for 'Unsubstantiated' CBD Health Claims

The warning letter included some examples of how Curaleaf Hemp products have been marketed on the company's social media accounts.

July 24, 2019

Finance

Read the Public Comments to the FDA on CBD Policy

The 2018 Farm Bill didn’t legalize CBD, per se; rather, the descheduling of hemp created a legal gray area for the cannabinoid, one which the FDA is working to clarify this year.

July 18, 2019

International

Cannabis Stocks Rally After FDA Says It Will Speed Up Effort to Create Rules for CBD

The FDA said it is expediting its effort to create a regulatory framework for CBD with plans to publish a report on its progress by early fall.

July 16, 2019